Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. (Q46114623)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

title

Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Roger M. Phillips

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

author name string

Arun Jain

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Gino Lenaz

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Mario Beer

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

Rajiv Puri

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

language of work or name

English

0 references

publication date

20 February 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

volume

73

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

page(s)

1083-1086

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

EO9: a novel bioreductive alkylating indoloquinone with preferential solid tumour activity and lack of bone marrow toxicity in preclinical models

21 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

EO9 phase II study in advanced breast, gastric, pancreatic and colorectal carcinoma by the EORTC Early Clinical Studies Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

A randomized phase II study with two schedules of the novel indoloquinone EO9 in non-small-cell lung cancer: a study of the EORTC Early Clinical Studies Group (ECSG)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

Phase II marker lesion study with intravesical instillation of apaziquone for superficial bladder cancer: toxicity and marker response

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

A single immediate postoperative instillation of chemotherapy decreases the risk of recurrence in patients with stage Ta T1 bladder cancer: a meta-analysis of published results of randomized clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

A prospective European Organization for Research and Treatment of Cancer Genitourinary Group randomized trial comparing transurethral resection followed by a single intravesical instillation of epirubicin or water in single stage Ta, T1 papillary ca

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

Effect of intravesical mitomycin C on recurrence of newly diagnosed superficial bladder cancer: interim report from the Medical Research Council Subgroup on Superficial Bladder Cancer (Urological Cancer Working Party).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2007.12.062

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.UROLOGY.2007.12.062

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19232688%20AND%20SRC:MED&resulttype=core&format=json

21 January 2020

1 reference